XL413   Click here for help

GtoPdb Ligand ID: 8113

Synonyms: BMS-863233 | BMS863233 | XL-413
PDB Ligand
Compound class: Synthetic organic
Comment: XL413 was developed as a selective inhibitor of cell division cycle 7 (CDC7) [1] and was investigated for its antineoplastic effects.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 2
Rotatable bonds 1
Topological polar surface area 70.92
Molecular weight 289.06
XLogP 3.31
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Clc1ccc2c(c1)c1[nH]c(nc(=O)c1o2)C1CCCN1
Isomeric SMILES Clc1ccc2c(c1)c1[nH]c(nc(=O)c1o2)[C@@H]1CCCN1
InChI InChI=1S/C14H12ClN3O2/c15-7-3-4-10-8(6-7)11-12(20-10)14(19)18-13(17-11)9-2-1-5-16-9/h3-4,6,9,16H,1-2,5H2,(H,17,18,19)/t9-/m0/s1
InChI Key JJWLXRKVUJDJKG-VIFPVBQESA-N
No information available.
Summary of Clinical Use Click here for help
XL413 did not progress beyond Phase 1 clinical trial investigation. Clinical trials for haematologic cancer and advanced and/or metastatic solid tumours were terminated.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
CDC7 is a protein kinase involved in control of the S-phase of the cell cycle, at the level of chromosmal DNA replication [...]. Inhibitors were developed as potential antineoplastics based on their ability to cause cell-cycle arrest and p53-independent tumour cell death.